Medicaid GLP-1 obesity coverage reaches 12 states, with Rhode Island dropping out October 1

Twelve state Medicaid fee-for-service programs paid for GLP-1 medications prescribed for obesity as of early September, and Rhode Island's elimination of weight-management coverage takes effect October 1, which would bring the total to 11 ^[1].

The 12-state figure comes from a state-by-state review of current Medicaid programs ^[1]. KFF's count in January 2026 was 13, itself down from 16 in October 2025 ^[1]. Massachusetts accounted for the most recent drop: MassHealth stopped paying for obesity-only prescriptions on July 1, 2026, a change affecting about 22,000 members, while continuing to cover the drugs for type 2 diabetes, sleep apnea with obesity, MASH and cardiovascular risk reduction ^[1].

Massachusetts was not the first to leave. Medi-Cal Rx ended weight-loss coverage for Saxenda, Wegovy and Zepbound on January 1, 2026, keeping prior-authorization coverage for FDA-approved uses such as type 2 diabetes, cardiovascular disease and kidney disease, with an exception for children under the EPSDT benefit ^[1]. Pennsylvania ended GLP-1 coverage for weight loss in adults 21 and older the same day ^[1]. Michigan narrowed its criteria on that date to morbid obesity and documented failure of alternatives, honoring existing approvals for their six-month terms ^[1]. North Carolina stopped covering Wegovy and Zepbound for obesity alone on October 1, 2025, and KFF reports the obesity benefit was reinstated there in December 2025 ^[1].

A federal provision drives the pattern. Under 42 U.S.C. § 1396r-8(d)(2), states may strike "agents when used for anorexia, weight loss, or weight gain" from their Medicaid formularies, language that dates to 1990 and predates GLP-1s ^[1]. The same law does not let states exclude diabetes drugs, so tirzepatide sold as Mounjaro remains covered in every state Medicaid program, generally with prior authorization ^[1]. Coverage for the obesity indication is optional, and states that do cover a GLP-1 for a non-diabetes reason tend to narrow it: West Virginia's criteria took effect July 1, 2025, and Louisiana's on June 5, 2025, both requiring adults 18 and older with moderate-to-severe obstructive sleep apnea, an apnea-hypopnea index of 15 or higher, a BMI of 30 or more, and no diabetes, with six-month approvals renewed only after at least 5% weight loss ^[1].

Getting on a formulary is not the same as getting a yes. Federal Medicaid managed care rules set outer limits of 72 hours for expedited prior authorization decisions and 14 calendar days for standard ones, and appeal windows run 30 to 60 days depending on the state ^[1]. State criteria documents point to recurring paperwork gaps: dated records of diet and exercise programs instead of a patient's own account, comorbidity codes missing from the prescription, and in some states restrictions on which prescriber types may write it ^[1]. No state, CMS or MACPAC source publishes first-submission approval rates or appeal success rates for these drugs ^[1].

Counts also vary by who is counting. An aggregator, glpchart.com, reported 20 programs covering Wegovy or Zepbound for weight loss on August 28, 2026, a figure that conflicts with state bulletins for California, New Hampshire and Pennsylvania ^[1].

Outside Medicaid, access is thinner. A 2024 KFF analysis found 1% of Marketplace plans covered Saxenda or Wegovy for weight loss and none covered Zepbound for weight loss, and a review of 2026 plans found 26 carriers out of roughly 300 nationwide offering GLP-1 coverage for obesity, most limited to enrollees with a BMI of at least 40 ^[2]. About 12% of U.S. adults reported using a GLP-1 medication as of late 2025 ^[2].

Why it matters for patients

For a Medicaid enrollee who has obesity but not diabetes, whether the drug is paid for depends on the state they live in rather than on their diagnosis ^[1]. Ending the obesity benefit does not end coverage of the same molecule prescribed for type 2 diabetes, but the prescription has to match a diagnosis the patient actually has; recording a diabetes diagnosis that is not real to obtain coverage is fraud ^[1]. Where obesity coverage survives, the route runs through prior authorization criteria that states publish ^[1]. For people paying cash, compounded tirzepatide is not a Medicaid benefit, and the market median first-month price was $299 as of September 3, 2026 ^[1]. Those with commercial coverage can use a manufacturer savings card that brings copays as low as $25 a month ^[1]. How often Medicaid prior authorization requests succeed has not been disclosed ^[1].

What happens next

Rhode Island's weight-management cut takes effect October 1, which would leave 11 fee-for-service programs covering GLP-1s for obesity ^[1]. Preferred drug lists and prior authorization criteria, which states revise quarterly, are where the current rules are written down ^[1].